Inventiva S.A. (NASDAQ:IVA) shares gapped up before the market opened on Friday . The stock had previously closed at $14.64, but opened at $15.10. Inventiva shares last traded at $15.10, with a volume of 220 shares traded.
Separately, Societe Generale downgraded Inventiva from a “buy” rating to a “sell” rating in a report on Monday, March 8th.
The company has a current ratio of 9.56, a quick ratio of 9.54 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $583.31 million and a price-to-earnings ratio of -12.96. The company’s 50 day moving average is $14.10.
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
Featured Story: Relative Strength Index
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.